☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Abecma
BMS' Abecma (Idecabtagene Vicleucel) Receives EC's Conditional Approval for Relapsed and Refractory Multiple Myeloma
August 20, 2021
BMS and bluebird bio's Abecma (idecabtagene vicleucel) Receive the US FDA's Approval as the First Anti-BCMA CAR T Cell Therapy for...
March 29, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.